NO20013220L - Trombin inhibitorer - Google Patents

Trombin inhibitorer

Info

Publication number
NO20013220L
NO20013220L NO20013220A NO20013220A NO20013220L NO 20013220 L NO20013220 L NO 20013220L NO 20013220 A NO20013220 A NO 20013220A NO 20013220 A NO20013220 A NO 20013220A NO 20013220 L NO20013220 L NO 20013220L
Authority
NO
Norway
Prior art keywords
thrombin inhibitors
formula
anticoagulants
class
compounds
Prior art date
Application number
NO20013220A
Other languages
English (en)
Other versions
NO321739B1 (no
NO20013220D0 (no
Inventor
Koo Lee
Won Hyuk Jung
Cheol Won Park
Sang Koo Lee
Sun Hwa Lee
Hee Dong Park
Original Assignee
Lg Ci Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Ci Ltd filed Critical Lg Ci Ltd
Publication of NO20013220D0 publication Critical patent/NO20013220D0/no
Publication of NO20013220L publication Critical patent/NO20013220L/no
Publication of NO321739B1 publication Critical patent/NO321739B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
NO20013220A 1998-12-29 2001-06-27 Nye forbindelser som er trombin-inhibitorer NO321739B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19980060266 1998-12-29
KR1019990033490A KR20000047461A (ko) 1998-12-29 1999-08-14 트롬빈 억제제
PCT/KR1999/000830 WO2000039124A1 (en) 1998-12-29 1999-12-29 Thrombin inhibitors

Publications (3)

Publication Number Publication Date
NO20013220D0 NO20013220D0 (no) 2001-06-27
NO20013220L true NO20013220L (no) 2001-08-27
NO321739B1 NO321739B1 (no) 2006-06-26

Family

ID=26634497

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013220A NO321739B1 (no) 1998-12-29 2001-06-27 Nye forbindelser som er trombin-inhibitorer

Country Status (22)

Country Link
US (2) US6492402B1 (no)
EP (1) EP1140918B1 (no)
JP (1) JP3847092B2 (no)
KR (2) KR20000047461A (no)
CN (1) CN1149210C (no)
AT (1) ATE273305T1 (no)
AU (1) AU765417B2 (no)
BR (1) BR9916678A (no)
CA (1) CA2355281A1 (no)
CZ (1) CZ20012429A3 (no)
DE (1) DE69919397T2 (no)
DK (1) DK1140918T3 (no)
ES (1) ES2226482T3 (no)
HK (1) HK1044936A1 (no)
HU (1) HUP0104500A3 (no)
IL (1) IL143545A (no)
NO (1) NO321739B1 (no)
NZ (1) NZ513174A (no)
RU (1) RU2221808C2 (no)
TR (1) TR200101899T2 (no)
WO (1) WO2000039124A1 (no)
ZA (1) ZA200104780B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK14222001A3 (sk) * 1999-04-09 2002-07-02 Basf Aktiengesellschaft Prekurzory trombínových inhibítorov
DE19933861A1 (de) 1999-07-23 2001-01-25 Basf Ag Verfahren zur Herstellung von 2-Aminomethyl-4-cyano-thiazol
DE19934066A1 (de) * 1999-07-23 2001-01-25 Basf Ag Verfahren zur Herstellung von 4-Cyano-2-aminomethylthiazol
DE10049937A1 (de) * 2000-10-06 2002-04-11 Knoll Ag Niedermolekulare Inhibitoren von Serinproteasen mit Polyhydroxyalkyl- und Polyhydroxycycloalkylresten
KR100447421B1 (ko) 2001-04-04 2004-09-07 주식회사 엘지생명과학 5-(아미노메틸)-2-티오펜카보니트릴 염산염의 연속반응에의한 새로운 제조방법
RU2004131204A (ru) * 2002-03-22 2005-04-10 Эл Джи Лайф Сайенсиз Лтд. (Kr) НОВЫЕ КРИСТАЛЛИЧЕСКИЕ ФОРМЫ (2S)-N-5-[АМИНО(ИМИНО)МЕТИЛ]-2-ТИЕНИЛМЕТИЛ-1-(2R)- [(КАРБОКСИМЕТИЛ)АМИНО]-3 ,3-Д ИФЕНИЛПРОПАНОИЛ-2-ПИРРОЛИДИНКАРБОКСАМИДА·nH2O
WO2003080602A1 (en) * 2002-03-22 2003-10-02 Lg Life Sciences Ltd. Maleic acid salt of (2s)-n-{5-[amino(imino)methyl]-2-thienyl}methyl-1-{(2r)-2-[(carboxymethyl)amino]3,3-diphenylpropanoyl}-2-pyrrolidine carboxamide and a process for
WO2004002985A1 (en) * 2002-06-27 2004-01-08 Lg Life Sciences Ltd. Peptidic thrombin inhibitor compound
US7097967B2 (en) 2002-10-24 2006-08-29 Lg Life Sciences Ltd. Method of predicting drug-food interaction
US7399870B2 (en) * 2004-03-30 2008-07-15 Wyeth Synthesis of pyrrole-2-carbonitriles
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US7678917B2 (en) * 2005-09-01 2010-03-16 Hoffman-La Roche Inc. Factor Xa inhibitors
CN110668988A (zh) 2005-10-07 2020-01-10 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek抑制剂的吖丁啶
BRPI0712021A2 (pt) 2006-05-23 2012-01-03 Irm Llc composto e composiÇÕes como inibidores da protease ativadora de canal
JP2008115178A (ja) * 2006-11-03 2008-05-22 Ajinomoto Co Inc ジフェニルアラニン−Ｎｉ（ＩＩ）錯体の製造方法
MX2009008518A (es) 2007-02-09 2009-08-20 Irm Llc Compuestos y composiciones como inhibidores de la proteasa activadora de canal.
WO2008135525A2 (en) * 2007-05-02 2008-11-13 Boehringer Ingelheim International Gmbh Substituted azetidines, manufacturing and use thereof as medicaments
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
WO2012058645A1 (en) * 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
NZ706723A (en) 2012-10-12 2018-07-27 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
KR20150132148A (ko) 2013-03-15 2015-11-25 베르선 코포레이션 세린 프로타아제 억제제로서의 다중 치환된 방향족 화합물
KR20150130405A (ko) 2013-03-15 2015-11-23 베르선 코포레이션 트롬빈의 억제제로서의 할로게노피라졸
CA2960790A1 (en) 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
RU2017131562A (ru) 2015-02-27 2019-03-27 Версеон Корпорейшн Замещенные пиразольные соединения как ингибиторы сериновых протеаз
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
KR20240019857A (ko) 2017-03-01 2024-02-14 아칠리온 파르마세우티칼스 인코포레이티드 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
BR112020024148A2 (pt) * 2018-05-29 2021-03-30 Omeros Corporation Compostos, composição farmacêutica, e, métodos para identificação de uma pequena molécula capaz de inibir masp-2 e para o tratamento de uma doença ou transtorno associado a masp-2
BR112021004263A2 (pt) 2018-09-06 2021-05-25 Achillion Pharmaceuticals, Inc. formas mórficas de danicopano
JP2022502500A (ja) 2018-09-25 2022-01-11 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ阻害剤の形態
JP2022519924A (ja) * 2019-03-22 2022-03-25 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体媒介性障害の治療のための医薬化合物
AU2020395306A1 (en) 2019-12-04 2022-06-30 Omeros Corporation MASP-2 inhibitors and methods of use
CA3159172A1 (en) 2019-12-04 2021-06-10 Michael Cicirelli Masp-2 inhibitors and methods of use
WO2023183405A2 (en) * 2022-03-22 2023-09-28 Alexion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
IL112795A (en) * 1994-03-04 2001-01-28 Astrazeneca Ab Derivatives of peptides as antithrombotic drugs, their preparation, and pharmaceutical preparations containing them
EA002767B1 (ru) 1995-02-10 2002-08-29 Басф Акциенгезельшафт Ингибиторы тромбина
US5914319A (en) * 1995-02-27 1999-06-22 Eli Lilly And Company Antithrombotic agents
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
IL123986A (en) * 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
AU2424499A (en) * 1998-01-26 1999-08-09 Basf Aktiengesellschaft Heterocyclic amidines as callicrein protease inhibitors
CN1289341A (zh) * 1998-01-26 2001-03-28 Basf公司 凝血酶抑制剂

Also Published As

Publication number Publication date
ZA200104780B (en) 2003-06-12
IL143545A (en) 2005-08-31
KR20010086468A (ko) 2001-09-12
BR9916678A (pt) 2001-10-16
RU2221808C2 (ru) 2004-01-20
JP3847092B2 (ja) 2006-11-15
DE69919397D1 (de) 2004-09-16
CA2355281A1 (en) 2000-07-06
ES2226482T3 (es) 2005-03-16
JP2002533460A (ja) 2002-10-08
US6864249B2 (en) 2005-03-08
IL143545A0 (en) 2002-04-21
EP1140918B1 (en) 2004-08-11
KR20000047461A (ko) 2000-07-25
HUP0104500A2 (hu) 2002-04-29
KR100462974B1 (ko) 2004-12-23
US6492402B1 (en) 2002-12-10
US20030134801A1 (en) 2003-07-17
DK1140918T3 (da) 2004-12-20
WO2000039124A1 (en) 2000-07-06
TR200101899T2 (tr) 2001-12-21
AU1895100A (en) 2000-07-31
CN1332737A (zh) 2002-01-23
CZ20012429A3 (cs) 2001-10-17
NO321739B1 (no) 2006-06-26
NZ513174A (en) 2003-10-31
NO20013220D0 (no) 2001-06-27
HUP0104500A3 (en) 2002-06-28
DE69919397T2 (de) 2005-07-28
AU765417B2 (en) 2003-09-18
ATE273305T1 (de) 2004-08-15
CN1149210C (zh) 2004-05-12
EP1140918A1 (en) 2001-10-10
HK1044936A1 (zh) 2002-11-08

Similar Documents

Publication Publication Date Title
DE69919397D1 (de) Thrombin-inhibitoren
ATE297203T1 (de) Antithrombotische mitteln
CY1107634T1 (el) Φαρμακευτικη συνθεση
ATE306261T1 (de) Antithrombosemittel
EA199900937A1 (ru) Фармацевтические композиции, содержащие вориконазол
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
ATE272633T1 (de) Aromatische amiden
NO20003018D0 (no) Triazinangiogenese-inhibitorer
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
SE9203825D0 (sv) Dual inhibitors of no synthase and cyclooxygenase, process for their preparation and therapeutical compositions containing them
EE200200045A (et) Asendatud oksoasaheterotsüklüülühendid, farmatseutiline kompositsioon ja vaheühendid
TR200002182T2 (tr) İkame edilmiş aksozaherosayklil faktör xa inhibitörleri
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
DE69931393D1 (de) Antithrombotische amide
NO991494D0 (no) <beta>-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer
EA200500312A1 (ru) Новые спироконденсированные хиназолиноны и их применение в качестве ингибиторов фосфодиэстераз
DK0715623T3 (da) Blodpladeaggregationsinhibitorer
UY26780A1 (es) Cicloalquil avb3 antagonistas
CO5261493A1 (es) Procedimiento y compuestos para la inhibicion de la mrp1
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
DK0804418T3 (da) Platelataggregationshæmmere
ATE308540T1 (de) Antithrombosemittel
ATE253359T1 (de) Antithrombotische mittel
NO20022977D0 (no) Substituerte homopiperidinylbenzimidazolanaloger som fundiske relaksanter